期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

非小细胞肺癌T细胞CTLA-4免疫靶向治疗基础与转化性研究现状的思考 被引量：1

CTLA-4 T cells immune targeted therapy based and status of transformation research in non-small cell lung cancer
下载PDF
导出
摘要 细胞毒T淋巴细胞相关抗原4(CTLA-4)是一种白细胞分化抗原,参与免疫反应的负调节。随着非小细胞肺癌(NSCLC)的治疗模式由驱动基因靶向治疗向免疫靶向治疗的转变,CDLA-4已成为一个新的研究热点。本文梳理近年来CTLA-4在NSCLC领域的研究情况,并结合相关基础及临床转化性研究进展作一综述。 Cytotoxic T lymphocyte associated（CTLA-4） is a kind of leukocyte differentiation antigens,it participates in the negative regulation of immune response. As the treatment of non-small cell lung cancer（ NSCLC） model by the driver gene targeted therapy to immune targeted therapy,CDLA-4 has become a new research hotspot. This article combing CDLA-4 research of NSCLC in recent years and reviews the connecting with the related basic and clinical research progress.
作者 余宗阳 莫享阳 欧阳学农
机构地区 福州南京军区福州总医院肿瘤科 福建中医药大学研究生院
出处 《临床肿瘤学杂志》 CAS 2015年第4期376-379,共4页 Chinese Clinical Oncology
关键词 非小细胞肺癌 免疫靶向治疗 细胞毒T淋巴细胞相关抗原4 T细胞 Non-small cell lung cancer Immune targeted therapy Cytotoxic T lymphocyte-associated antigen-4 T cell
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献28

  • 1Shimanovsky A, Jethava A, Dasanu CA. Immune alterations in malignant melanoma and current immunotherapy concepts [ J ]. Expert Opin Biol Ther, 2013, 13(10) : 1413-1427.
  • 2Rangachat6 D, Brahmer JR. Targeting the immune system in the treatment of non-small-cell lung cancer [ J ]. Curt Treat Options Oncol, 2013, 14(4) : 580-594.
  • 3Balzano C, Buonavista N, Rouvier E, et al. CTLA-4 and CD28 : similar proteins, neighbouring genes [ J ]. Int J Cancer Suppl, 1992, 7(2): 28-32.
  • 4Pardoll DM. The blockade of immune checkpoints in cancer im- munotherapy[ J]. Nat Rev Cancer, 2012, 12(4) : 252-264.
  • 5Callahan MK, Postow MA, Wolchok JD. Immunomodulatory ther- apy for melanoma: ipilimumab and beyond[ J]. Clin Dermatol, 2013, 31(2): 191-199.
  • 6Rudd CE, Taylor A, Schneider H. CD28 and CTLA-4 coreceptor expression and signal transduction[ J]. Immunol Rev, 2009, 229 (1) : 12-26.
  • 7Ikeda H, Old LJ, Schreiber RD. The roles of IFN gamma in pro- tection against tumor development and cancer immunoediting [ J ]. Cytokine Growth Factor Rev, 2002, 13(2) : 95-109.
  • 8Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape [ J ]. Nat Immunol, 2002, 3(11): 991-998.
  • 9Langer CJ. Emerging immunotherapies in the treatment of non- small cell lung cancer (NSCLC) : the role of immune checkpoint inhibitors [ J/OL ]. Am J Clin Oncol, 2014 [ 2014-10-11 ]. http ://www. ncbi. nlm. nih. gov/pubmed/24685885.
  • 10Wroblewski JM, Bixby DL, Borowski C, et al. Characterization of human non-small cell lung cancer (NSCLC) cell lines for expres- sion of MHC, co-stimulatory molecules and tumor-associated anti- gens[J]. Lung Cancer, 2001, 33(2-3) : 181-194.

同被引文献14

  • 1Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015 [ J]. CA Cancer J Clin, 2015, 65(1) : 5-29.
  • 2Song B, Zhan H, Bian Q, et al. Knockdown of CUIAB inhibits proliferation and promotes apoptosis of colorectal cancer cells through suppressing the Wnt/β-catenin signaling pathway[ J]. lnt J Clin Exp Pathol, 2015, 8 (9) : 10394-10402.
  • 3Qian Y, Yuan J, Hu H, et al. The CUL4B/AKT/β-catenin axis restricts the accumulation of myeloid-derived suppressor cells to prohibit the establishment of a tumor-permissive microenvironme- nt[J]. Cancer Res, 2015, 75(23):5070-5083.
  • 4Yang Y, Liu R, Qiu R, et al. CRL4B promotes tumorigenesis by coordinating with SUV39H1/HP1/DNMT3A in DNA methylatio- n-based epigenetic silencing [ J ]. Oncogene, 2015, 34 ( 1 ) : 104 -118.
  • 5Lee J, Zhou P. Pathogenic role of the CRL4 ubiquitin ligase in human disease [ J/OL ]. Front Oncol, 2012 [ 2015-05-22 ]. http ://www. ncbi. nlm. nih. gov/pmc/articles/pmid/22649780.
  • 6Kerzendorfer C, Whibley A, Carpenter G, et al. Mutations in Cullin 4B result in a human syndrome associated with increased camptothecin-induced topoisomerase I-dependent DNA breaks [J]. Hum Mol Genet. 2010, 19(7) :1324-1334.
  • 7Mok MT, Cheng AS. CUL4B: a novel epigenetic driver in Wnt/β-catenin-dependent hepatocarcinogenesis [ J]. J Pathol, 2015, 236(1) :1-4.
  • 8Yuan J, Han B, Hu H, et al. CUL4B activates Wnt/β-catenin signalling in hepatocellular carcinoma by repressing Wnt antago- nists[J]. J Pathol, 2015, 235(5):784-795.
  • 9Jiang T, Tang HM, Wu ZH, et al. Cullin 4B is a novel prognostic marker that correlates with colon cancer progression and pathogenesis[ J]. Med Oneol, 2013, 30(2): 534.
  • 10Chen Z, Shen BL, Fu QG, et al. CUL4B promotes proliferation and inhibits apoptosis of human osteosarcoma cells [ J ]. Oncol Rep, 2014, 32(5): 2047-2053.

引证文献1

二级引证文献2

临床肿瘤学杂志
2015年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部